Literature DB >> 36033209

Transgender Youth Experiences with Implantable GnRH Agonists for Puberty Suppression.

Brianna J Hobson1, Elle Lett2,3, Linda A Hawkins4, Robert A Swendiman5, Michael L Nance6, Nadia L Dowshen7.   

Abstract

This descriptive study reports caregiver experiences with GnRH agonist implants among a cohort of youth followed in a pediatric hospital-based gender clinic. We administered a survey to 36 of 55 eligible caregivers ascertaining demographics and satisfaction, with a medical record review of any surgical complications. The overwhelming majority (97.1%) reported satisfaction with the procedure and would undergo the implant procedure again (94.4%). The most frequent challenges noted were about affordability (39.8%) and insurance denials (39.8%). Implantable GnRH agonist can be used successfully in pediatric patients with gender dysphoria. Future policy should seek to address concerns regarding insurance approval and reimbursement. Copyright 2022, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  implant; insurance; patient satisfaction; puberty blockers; transgender youth

Year:  2022        PMID: 36033209      PMCID: PMC9398484          DOI: 10.1089/trgh.2021.0006

Source DB:  PubMed          Journal:  Transgend Health        ISSN: 2380-193X


  16 in total

1.  Insurance Coverage of Puberty Blocker Therapies for Transgender Youth.

Authors:  Jaime Stevens; Veronica Gomez-Lobo; Elyse Pine-Twaddell
Journal:  Pediatrics       Date:  2015-11-02       Impact factor: 7.124

2.  The histrelin implant: a novel treatment for central precocious puberty.

Authors:  Harry J Hirsch; David Gillis; David Strich; Boris Chertin; Amicur Farkas; Tzina Lindenberg; Hadassa Gelber; Irving M Spitz
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

Review 3.  Psychological and medical care of gender nonconforming youth.

Authors:  Stanley R Vance; Diane Ehrensaft; Stephen M Rosenthal
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

4.  Young adult psychological outcome after puberty suppression and gender reassignment.

Authors:  Annelou L C de Vries; Jenifer K McGuire; Thomas D Steensma; Eva C F Wagenaar; Theo A H Doreleijers; Peggy T Cohen-Kettenis
Journal:  Pediatrics       Date:  2014-09-08       Impact factor: 7.124

5.  Histrelin implantation in the pediatric population: A 10-year institutional experience.

Authors:  Robert A Swendiman; Maria G Vogiatzi; Craig A Alter; Michael L Nance
Journal:  J Pediatr Surg       Date:  2018-09-08       Impact factor: 2.545

6.  Early Medical Treatment of Children and Adolescents With Gender Dysphoria: An Empirical Ethical Study.

Authors:  Lieke Josephina Jeanne Johanna Vrouenraets; A Miranda Fredriks; Sabine E Hannema; Peggy T Cohen-Kettenis; Martine C de Vries
Journal:  J Adolesc Health       Date:  2015-06-25       Impact factor: 5.012

7.  Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.

Authors:  Erica A Eugster; William Clarke; Gad B Kletter; Peter A Lee; E Kirk Neely; Edward O Reiter; Paul Saenger; Dorothy Shulman; Lawrence Silverman; Lisa Flood; William Gray; David Tierney
Journal:  J Clin Endocrinol Metab       Date:  2007-02-27       Impact factor: 5.958

8.  Trends in the use of puberty blockers among transgender children in the United States.

Authors:  Carla Marisa Lopez; Daniel Solomon; Susan D Boulware; Emily R Christison-Lagay
Journal:  J Pediatr Endocrinol Metab       Date:  2018-06-27       Impact factor: 1.634

Review 9.  The effect of early puberty suppression on treatment options and outcomes in transgender patients.

Authors:  Leonidas Panagiotakopoulos; Veenod Chulani; Atsuko Koyama; Krista Childress; Michelle Forcier; Gwen Grimsby; Katherine Greenberg
Journal:  Nat Rev Urol       Date:  2020-09-23       Impact factor: 14.432

Review 10.  Threats to validity in retrospective studies.

Authors:  Cindy Tofthagen
Journal:  J Adv Pract Oncol       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.